Chemours Falls After Q3 Miss as Options Flip Defensive

The Chemours Company has moved sharply after its Q3 results, with the stock down nearly 2% on the week to $13.09 and options traders reversing from an unusually bullish stance into their most defensive posture in months.

The options swing is the most striking development since the pre-earnings note. Going into the print, the put/call ratio sat at 0.44, well below its 20-day average in a signal that leaned bullish. It has since collapsed to 0.35, nearly 2.5 standard deviations below that same 20-day average of 0.51. That is a move in the wrong direction for longs: call positioning has surged relative to puts, but the stock dropped 3.3% on the day of the results, suggesting that call buyers got the positioning wrong. The PCR is now near the 52-week low of 0.14, meaning the market is running more call-heavy than at any point this year even as the stock slides, an unusual and somewhat contradictory setup.

Short interest offers a steadier picture. It edged up 0.65% over the past week to just under 9.95% of the free float, reversing a month-long decline that had brought it down 5% from October highs. At 14.9 million shares short, the position is meaningful but not escalating aggressively. The borrow market remains open: availability is an exceptionally generous 1,554%, meaning there are roughly fifteen shares available for every one on loan, and cost to borrow has drifted lower to 0.46%, down about 1.4% on the week. There is no squeeze mechanism here, shorts can add or cover freely.

The analyst response to the Q3 print has been immediate and negative. Truist Securities, the lone remaining Buy on the stock, lowered its target to $18 from $20 on November 4, following its own cut from $24 to $20 in mid-October. That sequence reflects a firm still constructive on the name but steadily repricing expectations lower. Mizuho had already downgraded to Neutral in mid-October, cutting its target to $15. Barclays initiated at Equal-Weight with a $16 target. The consensus sits at Hold with eight Hold ratings against two Buys, and the mean price target is $16.90, implying around 29% upside from current levels. The stock's EPS surprise factor score ranks in the 97th percentile of the universe, meaning Chemours has a strong track record of beating estimates, but that history offered little protection this week. The EV/EBITDA multiple is running at 6.3x, and the PE at 7.7x, both modest levels that reflect the market's uncertainty about earnings trajectory rather than any premium.

The insider data provides a useful reference point. In early August, following the prior quarterly results, a cluster of insiders bought the stock in the mid-to-high $14 to $15.80 range: the CEO, CFO, two directors and several other insiders all made open-market purchases totalling net positive 31,537 shares across the 90-day window. Those trades were made at prices above where the stock trades now at $13.09, so none of them are in the money. BlackRock remains the largest institutional holder at around 15.5% of shares, having added roughly 897,000 shares in the September quarter. JP Morgan Asset Management added 772,000 shares in the same period. Neither position has been updated since September 30, so the current picture post-earnings is unknown.

Peer performance adds texture. Close correlate TROX fell 7.6% on the week, suggesting the TiO2 segment remains under broad pressure. CE bucked the trend, gaining 3.6%, while OLN added 5.9%, indicating the weakness is more Chemours and TiO2-specific than a sector-wide selloff.

The next earnings event is not until February 19, giving the market 107 days to reassess. The key questions in the interim are whether Truist's Buy rating survives further target erosion, and whether the insider buying cluster from August proves prescient or simply early.